Ultimovacs to Present Poster at 2024 ASCO Annual Meeting

Oslo, June 1, 2024 - Ultimovacs ASA, a clinical-stage biotechnology firm focusing on immunotherapeutic cancer vaccines, has announced that data from its Phase II clinical trial, INITIUM (NCT04382664), will be showcased during the 2024 ASCO Annual Meeting. The gathering is scheduled from May 31 to June 4, 2024, both in Chicago, IL, and online. Details of the late-breaking abstract related to this presentation can be accessed on the 2024 ASCO website.

INITIUM is a randomized, comparative, multicenter Phase II trial sponsored by Ultimovacs. The trial explores the efficacy of the company's lead cancer vaccine candidate, UV1, in combination with the checkpoint inhibitors ipilimumab and nivolumab as a first-line treatment for patients with unresectable or metastatic malignant melanoma. The study was conducted across 39 hospitals in the U.S., U.K., Belgium, and Norway, enrolling a total of 156 patients between June 2020 and July 2022.

The poster presentation will highlight significant findings and analyses after a minimum follow-up period of 18 months for the patients involved in the trial. The presentation details are as follows:

- Abstract Number: LBA9519
- Abstract Title: "Ipilimumab and nivolumab plus UV1, an anticancer vaccination against telomerase, in advanced melanoma."
- Session Title: Poster Session – Melanoma/Skin Cancers
- Poster Board: 303
- Date and Time: June 1, 2024, 1:30 PM – 4:30 PM (CT)
- Presenter: Paul Lorigan, Professor of Medical Oncology at the University of Manchester and Investigator in the INITIUM study

Following the presentation at the ASCO Annual Meeting, the poster will be available online in the Investor section of Ultimovacs' website.

About Ultimovacs

Ultimovacs is a leader in the development of innovative immunotherapeutic cancer vaccines with broad potential applications. The company's main cancer vaccine candidate, UV1, targets human telomerase (hTERT), an antigen found in 85-90% of all cancer types at various stages of tumor growth. The extensive clinical program includes Phase II trials in five different cancer indications, involving more than 670 patients. These trials aim to demonstrate the efficacy of UV1 in combination with other immunotherapies across multiple cancer types that express telomerase and for which patients have significant unmet medical needs. UV1 is designed to be a universal, off-the-shelf solution that is easy to use and is protected by patents owned by Ultimovacs. Additionally, Ultimovacs holds all rights to the proprietary TET technology platform, which may be used for future formulations in various solid tumor indications. The company is publicly traded on the Euronext Oslo Stock Exchange under the ticker symbol ULTI.OL.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!